European Urology Focus

Slides:



Advertisements
Similar presentations
Volume 69, Issue 5, Pages (May 2016)
Advertisements

Volume 68, Issue 6, Pages (December 2015)
European Urology Focus
Volume 164, Issue 6, Pages (December 2000)
Volume 155, Issue 3, Pages (March 1996)
Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-
Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand  Bannakij Lojanapiwat, Choosak Pripatnanont,
Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone.
Volume 60, Issue 2, Pages (August 2011)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
European Urology Focus
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer  Miguel.
Testosterone Therapy in Men With Prostate Cancer
David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono 
Volume 70, Issue 6, Pages (December 2016)
Volume 68, Issue 6, Pages e129-e131 (December 2015)
Volume 52, Issue 5, Pages (November 2007)
Volume 67, Issue 4, Pages (April 2015)
Volume 74, Issue 2, Pages (August 2018)
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.
Managing Nonmetastatic Castration-resistant Prostate Cancer
Advances in the Treatment of Metastatic Prostate Cancer
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration- resistant Prostate Cancer in the Era of Precision Oncology  Philipp.
Volume 63, Issue 2, Pages (February 2013)
Volume 65, Issue 5, Pages (May 2014)
Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer  Semini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, Gerhardt Attard, Kim.
Volume 65, Issue 3, Pages (March 2014)
Volume 65, Issue 1, Pages (January 2014)
Volume 71, Issue 1, Pages 1-3 (January 2017)
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Prostate Cancer Detection: A View of the Future
Volume 65, Issue 4, Pages (April 2014)
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
Volume 66, Issue 5, Pages (November 2014)
Volume 66, Issue 3, Pages (September 2014)
Volume 43, Issue 1, Pages (January 2003)
Volume 70, Issue 5, Pages (November 2016)
Laurent Boccon-Gibod  European Urology Supplements 
Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients  Timo F.W. Soeterik,
Luis Martínez-Piñeiro  European Urology Supplements 
Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers  Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 72, Issue 1, Pages (July 2017)
Volume 67, Issue 1, Pages (January 2015)
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.
Volume 73, Issue 5, Pages (May 2018)
Volume 75, Issue 1, Pages (January 2019)
Volume 71, Issue 6, Pages (June 2017)
What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006  Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,
Volume 66, Issue 6, Pages (December 2014)
The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.
Volume 70, Issue 6, Pages (December 2016)
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Volume 74, Issue 3, Pages (September 2018)
Volume 70, Issue 1, Pages (July 2016)
Volume 71, Issue 4, Pages (April 2017)
European Urology Oncology
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Volume 69, Issue 5, Pages (May 2016)
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
European Urology Oncology
Treatment Options in Prostate Cancer Once Primary Therapy Fails
Manfred Wirth, Peter Iversen, David McLeod, William See 
European Urology Oncology
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer  Adam Sharp,
Guru Sonpavde, MD, Teresa G. Hayes, MD  Mayo Clinic Proceedings 
European Urology Oncology
European Urology Oncology
European Urology Oncology
Presentation transcript:

European Urology Focus Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi- institutional Survey  David Lorente, Praful Ravi, Niven Mehra, Carmel Pezaro, Aurelius Omlin, Alexa Gilman, Miguel Miranda, Pasquale Rescigno, Michael Kolinsky, Nuria Porta, Diletta Bianchini, Nina Tunariu, Raquel Perez, Joaquin Mateo, Heather Payne, Leon Terstappen, Maarten IJzerman, Emma Hall, Johann de Bono  European Urology Focus  DOI: 10.1016/j.euf.2016.09.005 Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 1 Number of cycles of chemotherapy administered to patients with Response Evaluation Criteria in Solid Tumours (RECIST)–evaluable disease and bone-only metastatic castration-resistant prostate cancer (mCRPC). The figure summarises replies for Questions 5–8 (“How many cycles of docetaxel/cabazitaxel do you prescribe, on average, to mCRPC patients with RECIST-evaluable/bone only disease?”). European Urology Focus DOI: (10.1016/j.euf.2016.09.005) Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 2 Evaluation of prostate-specific antigen (PSA) progression criteria. The figure summarises replies for Question 12. Participants were shown three different PSA biomarker scenarios for patients with bone-only disease. The percentage of participants who believed the scenario corresponded to PSA progression is shown in the pie charts. Correct response: (A) No; (B) Yes; (C) Yes. European Urology Focus DOI: (10.1016/j.euf.2016.09.005) Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 3 Importance of different biomarkers in clinical decision-making (stopping therapy) in metastatic castration-resistant prostate cancer. The figure summarises replies for Question 19. Participants were asked to rank each of the different types of disease progression listed from 1 (extremely important) to 6 (not at all important) in their clinical decisions to switch or stop therapy. RECIST=Response Evaluation Criteria in Solid Tumours; PSA=prostate-specific antigen; CTCs=circulating tumour cells. European Urology Focus DOI: (10.1016/j.euf.2016.09.005) Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 4 Decision-making for different biomarker scenarios. The figure summarises replies for Question 22. Participants were shown four different biomarker scenarios combining prostate-specific antigen (PSA), circulating tumor cells (CTCs), and bone scan findings for clinically stable patients. The proportion of participants who would switch or stop therapy at 12 wk is shown in the pie charts. European Urology Focus DOI: (10.1016/j.euf.2016.09.005) Copyright © 2016 European Association of Urology Terms and Conditions